The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib
Ruxolitinib is increasingly being utilized for the treatment of myelofibrosis and polycythemia vera, but the potential for hepatic toxicity is poorly understood. We performed a retrospective review of hepatic damage occurring in patients with myeloproliferative neoplasms receiving ruxolitinib. Relev...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2019/3294046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568314569687040 |
|---|---|
| author | Douglas Tremblay Juan Putra Alexander Vogel Adam Winters Ronald Hoffman Thomas D. Schiano Maria Isabel Fiel John O. Mascarenhas |
| author_facet | Douglas Tremblay Juan Putra Alexander Vogel Adam Winters Ronald Hoffman Thomas D. Schiano Maria Isabel Fiel John O. Mascarenhas |
| author_sort | Douglas Tremblay |
| collection | DOAJ |
| description | Ruxolitinib is increasingly being utilized for the treatment of myelofibrosis and polycythemia vera, but the potential for hepatic toxicity is poorly understood. We performed a retrospective review of hepatic damage occurring in patients with myeloproliferative neoplasms receiving ruxolitinib. Relevant histologic images of liver biopsies were reviewed by an experienced liver pathologist and reported to a multidisciplinary team including hepatology and hematology. A variety of liver pathology was observed including extramedullary hematopoiesis, obliterative portal venopathy, and drug-induced liver injury. In all cases reviewed, the liver biopsy had significant treatment implications. We conclude that hepatology referral and liver biopsy in patients receiving ruxolitinib therapy with biochemical evidence of liver injury reveals a variety of etiologies which have significant treatment impact. Clinicians should be aware of the potential causes of liver damage in this population and initiate prompt referral and liver biopsy. |
| format | Article |
| id | doaj-art-c681ce0f52e94a0cbc72ae54da44e755 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-c681ce0f52e94a0cbc72ae54da44e7552025-02-03T00:59:17ZengWileyCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/32940463294046The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with RuxolitinibDouglas Tremblay0Juan Putra1Alexander Vogel2Adam Winters3Ronald Hoffman4Thomas D. Schiano5Maria Isabel Fiel6John O. Mascarenhas7Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Medicine, Division of Liver Diseases, Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USATisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USARuxolitinib is increasingly being utilized for the treatment of myelofibrosis and polycythemia vera, but the potential for hepatic toxicity is poorly understood. We performed a retrospective review of hepatic damage occurring in patients with myeloproliferative neoplasms receiving ruxolitinib. Relevant histologic images of liver biopsies were reviewed by an experienced liver pathologist and reported to a multidisciplinary team including hepatology and hematology. A variety of liver pathology was observed including extramedullary hematopoiesis, obliterative portal venopathy, and drug-induced liver injury. In all cases reviewed, the liver biopsy had significant treatment implications. We conclude that hepatology referral and liver biopsy in patients receiving ruxolitinib therapy with biochemical evidence of liver injury reveals a variety of etiologies which have significant treatment impact. Clinicians should be aware of the potential causes of liver damage in this population and initiate prompt referral and liver biopsy.http://dx.doi.org/10.1155/2019/3294046 |
| spellingShingle | Douglas Tremblay Juan Putra Alexander Vogel Adam Winters Ronald Hoffman Thomas D. Schiano Maria Isabel Fiel John O. Mascarenhas The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib Case Reports in Hematology |
| title | The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib |
| title_full | The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib |
| title_fullStr | The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib |
| title_full_unstemmed | The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib |
| title_short | The Implications of Liver Biopsy Results in Patients with Myeloproliferative Neoplasms Being Treated with Ruxolitinib |
| title_sort | implications of liver biopsy results in patients with myeloproliferative neoplasms being treated with ruxolitinib |
| url | http://dx.doi.org/10.1155/2019/3294046 |
| work_keys_str_mv | AT douglastremblay theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT juanputra theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT alexandervogel theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT adamwinters theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT ronaldhoffman theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT thomasdschiano theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT mariaisabelfiel theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT johnomascarenhas theimplicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT douglastremblay implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT juanputra implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT alexandervogel implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT adamwinters implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT ronaldhoffman implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT thomasdschiano implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT mariaisabelfiel implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib AT johnomascarenhas implicationsofliverbiopsyresultsinpatientswithmyeloproliferativeneoplasmsbeingtreatedwithruxolitinib |